Hospira ends search for CEO, naming Allergan veteran to the post

8 March 2011

The board of directors of US specialty pharma and medication delivery firm Hospira (NYSE: HSP) has ended its search since last summer for a new chief executive, electing Michael Ball, currently president of Allergan, to succeed the company's founding CEO, Christopher Begley, who will assume the role of executive chairman, effective end March.

Irvine, California-based Allergan is not planning to replace Mr Ball, instead, re-appointing chairman and CEO David Pyott to the role of president, role, which he formerly held from 1998 until 2006.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Pharmaceutical